ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Information for professionals for Nocutil:Gebro Pharma AG
Complete information for professionalsDDDÄnderungen anzeigenPrint 
Composition.Galenic FormIndication.UsageContra IndicationWarning restrictions.Interactions.Pregnancy
Driving abilityUnwanted effectsOverdoseEffectsPharm.kinetikPreclinicalOther adviceSwissmedic-Nr.
PackagesRegistration ownerLast update of information 
H01BA02 - DesmopressinATC-DDD Version 2016. Source: WHO
H - Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins

This group comprises all hormonal preparations for systemic use, except:
- Insulins, see A10.
- Anabolic steroids, see A14.
- Catecholamines, see C01C and R03C.
- Sex hormones, see G03.
- Sex hormones used in treatment of neoplastic diseases, see L02.
- Metreleptin used for treatment of complications of leptin deficiency in patients with generalised lipodystrophy is classified in A16AA.

The DDDs are generally based on the treatment or diagnosis of endocrine disorders.

H01 - Pituitary and Hypothalamic Hormones and Analogues
 
H01B - Posterior Pituitary Lobe Hormones

This group comprises posterior pituitary lobe hormones; extracts, purified natural hormones and synthetic analogues.

H01BA - Vasopressin and Analogues
 

The DDDs are based on the treatment of diabetes insipidus.
The DDD for terlipressin (as acetate) is based on treatment of bleeding oesophageal varices.

H01BA02 - Desmopressin
DoseRoute of administrationNote
   
 P 
 O 
 N 
2024 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home